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Abstract 
Colon cancer is the third most common cancer and the third largest cause of cancer-related death. 
Fluorouracil (5-FU) is the front-line chemotherapeutic agent for colon cancer. However, its response rate is 
less than 60%, even in combination with other chemotherapeutic agents. The side effects of 5-FU also 
limit its application. Nanoparticles have been used to deliver 5-FU, to increase its effectiveness and 
reduce side effects. Another common approach for colon cancer treatment is targeted therapy against 
the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway. A recently-invented inhibitor of this 
pathway, BEZ-235, has been tested in several clinical trials and has shown effectiveness and low side 
effects. Thus, it is a very promising drug for colon cancer treatment. The combination of these two drugs, 
especially nanoparticle-packed 5-FU and BEZ-235, has not been studied. In the present study, we 
demonstrated that nanoparticles of layered double hydroxide (LDH) loaded with 5-FU were more effective 
than a free drug at inhibiting colon cancer cell growth, and that a combination treatment with BEZ-235 
further increased the sensitivity of colon cancer cells to the treatment of LDH-packed 5-FU (LDH-5-FU). 
BEZ-235 alone can decrease colon cancer HCT-116 cell viability to 46% of the control, and the addition of 
LDH-5-FU produced a greater effect, reducing cell survival to 8% of the control. Our data indicate that the 
combination therapy of nanodelivered 5-FU with a PI3K/Akt inhibitor, BEZ-235, may promise a more 
effective approach for colon cancer treatment. 
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Abstract: Colon cancer is the third most common cancer and the third largest cause of 
cancer-related death. Fluorouracil (5-FU) is the front-line chemotherapeutic agent for colon 
cancer. However, its response rate is less than 60%, even in combination with other chemo-
therapeutic agents. The side effects of 5-FU also limit its application. Nanoparticles have been 
used to deliver 5-FU, to increase its effectiveness and reduce side effects. Another common 
approach for colon cancer treatment is targeted therapy against the phosphoinositide 3-kinase 
(PI3K)/protein kinase B (Akt) pathway. A recently-invented inhibitor of this pathway, BEZ-235, 
has been tested in several clinical trials and has shown effectiveness and low side effects. Thus, 
it is a very promising drug for colon cancer treatment. The combination of these two drugs, 
especially nanoparticle-packed 5-FU and BEZ-235, has not been studied. In the present study, 
we demonstrated that nanoparticles of layered double hydroxide (LDH) loaded with 5-FU were more 
effective than a free drug at inhibiting colon cancer cell growth, and that a combination treatment 
with BEZ-235 further increased the sensitivity of colon cancer cells to the treatment of LDH-packed 
5-FU (LDH-5-FU). BEZ-235 alone can decrease colon cancer HCT-116 cell viability to 46% of 
the control, and the addition of LDH-5-FU produced a greater effect, reducing cell survival to 8% 
of the control. Our data indicate that the combination therapy of nanodelivered 5-FU with a PI3K/
Akt inhibitor, BEZ-235, may promise a more effective approach for colon cancer treatment.
Keywords: layered double hydroxide (LDH), BEZ-235, 5-FU, colon cancer HCT-116 cells, 
cell death, apoptosis, PI3K/Akt/mTOR
Introduction
Colon cancer is the third most common cancer in humans and has a high mortality 
rate. The five-year survival rate for metastatic colon cancer is less than 10%. Many 
therapeutic approaches have been used for the treatment of colon cancer, including che-
motherapy, radiotherapy, targeted therapy, and immune therapy. Nanoparticles (NPs) 
have been used to control drug release. For example, polymer microsphere delivery 
allows slower and delayed drug release of valdecoxib, an inhibitor of cyclooxyyge-
nase-2 enzyme.1 Nanodelivery can also avoid the release of drug at pH 1.2–6.8, so 
that the drug is not released in the stomach, ensuring colonic release.2 Fluorouracil 
is the drug of first choice in chemotherapy for colon cancer. However, its response 
rate is less than 60%, even in combination with other chemotherapeutic agents.3 Drug 
resistance is a major issue in the clinical application of 5-FU.4 In addition, the severe 
side effects of 5-FU limit its clinical application at high dosages. The bioavailability 
of 5-FU is poor and its metabolism is rapid. Thus, an effective delivery mechanism for 
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5-FU is needed for clinical application.5 In order to increase 
the effectiveness of 5-FU and reduce its side effects, several 
approaches have been employed, including combinatorial 
application with other anticancer agents and the application 
of nanotechnology for its delivery.
Recently, several types of NPs have been used to deliver 
5-FU to increase treatment efficacy and reduce side effects, 
including layered double hydroxide (LDH), liposomes and silica-
based NPs.6–9 LDH is an inorganic NP with low toxicity, which 
has been used to deliver chemotherapeutic agents, including 
5-FU.10–13 Delivery by NPs can increase treatment efficacy and 
reduce side effects, as NP-5-FU can accumulate in tumor sites 
(due to vascular structural differences between the tumor and 
normal tissues). Nanoparticle-loaded drugs can also be taken up 
by cells through endocytosis. Therefore, their concentrations in 
cells are increased.14 LDH-packed 5-FU has been used together 
with curcumin and AllStars Hs Cell Death small interfering 
RNAs (siRNAs) to increase treatment efficacy,5,15 but has not 
been used with other anticancer agents, such as BEZ-235.
5-FU has been used most often together with oxaliplatin, 
to increase patient response to 5-FU.16,17 Furthermore, folic 
acid has been included in a treatment regime containing 5-FU 
and oxaliplatin. The chemotherapeutic agents irinotecan and 
leucovorin have been added to the combinational therapeutic 
regime with 5-FU.18,19 In addition, 5-FU has been used in com-
bination with immune therapy and targeted therapies against 
B-cell lymphoma 2 (Bcl-2), such as interferon-α, cetuximab, 
rapamycin, and siRNA.20–22 A phase III clinical trial showed 
that cetuximab significantly increased the effect of 5-FU in 
combination with the FOLFIRI regimen.23 Fluorouracil has 
also been used with a dual inhibitor of the phosphoinositide 
3-kinase (PI3K)/protein kinase B (Akt)/mammalian target 
of rapamycin (mTOR) pathway, PI-103.24
PI3K/Akt is a major survival pathway and plays a key 
role in many cancers, including colon cancer.25–28 Targeted 
therapy against the PI3K/Akt/mTOR pathway has been 
extensively studied in colon cancer. The pathway is associ-
ated also with resistance to chemotherapeutic drugs.29,30 BEZ-
235 is a new and very promising inhibitor of the PI3K/Akt 
pathway (due to its effectiveness and low side effects). It can 
inhibit the activity of both PI3K and mTOR and thus elimi-
nate the feedback activation of PI3K activity due to inhibition 
of mTOR. A recent study showed that BEZ-235 is effective 
on both PIK3CA-mutated and unmutated colon cancer cell 
lines.31 Therefore, BEZ-235 may soon be incorporated into 
the present treatment regime for colon cancer. However, 
combinational treatment with BEZ-235 and nanoparticle-
delivered 5-FU, especially the additive or even synergistic 
effect of their treatment, has not been well studied. In the 
present study, we investigated the treatment effect of LDH-
loaded 5-FU and BEZ-235 in the colon cancer cell line 
HCT-116. We found that the combination treatment could 
dramatically increase cancer cell death, both through cell 
cycle changes and apoptotic pathways.
Materials and methods
MgCl
2 
⋅6H
2
O, AlCl
3
⋅6H
2
O, NaOH, 5-FU, Tween® 20, protein 
lysis buffer, and Triton® 100 were purchased from Sigma-
Aldrich Corp (St Louis, MO, USA). Dulbecco’s Modified 
Eagle’s Medium (DMEM), PBS buffer, and Tris buffer were 
obtained from Life Technologies Corporation (Mulgrave, Victo-
ria, Australia). BEZ-235 was obtained from Cayman Chemical 
Company (Ann Arbor, MI, USA). The Annexin V-FITC Apop-
tosis detection kit was obtained from BD Biosciences (Franklin 
Lakes, NJ, USA). Mouse monoclonal antihuman Bcl-2 antibody 
and rabbit antihuman α-tubulin antibody were obtained from 
Cell Signaling Technology Inc (Danvers, MA, USA).
Preparation of lDh and lDh-5-FU
LDH was made by a standard method.5,12,13 The 5-FU/Mg
2
Al-
LDH hybrid (LDH-5-FU) was synthesized via ion exchange 
methods with a hydrothermal treatment. The synthetic pro-
cedure involved mixing 0.3 M MgCl
2 
and 0.1 M AlCl
3
 solu-
tion before quickly adding it to 0.15 M NaOH solution and 
stirring for 10 minutes. Then, LDH slurry was collected by 
centrifugation. The precipitation was resuspended into 40 mL 
of the basic solution containing 0.2 mm of 5-FU (neutral-
ized with dilute NaOH solution, with pH 8–9) for 1 hour. 
After washing two times, the LDH-5-FU was resuspended 
in 40 mL of distilled water and transferred to an autoclave 
(stainless steel with a teflon lining) and incubated at 100°C 
for 16 hours. After hydrothermal treatment, a transparent, 
homogeneous suspension of LDH-5FU was obtained.
Physicochemical characterization
The hydrodynamic particle size and the zeta potential of 
the LDH and LDH-5-FU nanohybrids were determined by 
dynamic light scattering (DLS). All measurements were car-
ried out at 25°C with photon correlation spectroscopy using a 
Zetasizer Nano ZS (Malvern Instruments Ltd, Malvern, UK). 
Each parameter was measured in triplicate and the average 
value was calculated. Transmission electron  microscopy 
(TEM) images were obtained using a JEM-1010A 
(JEOL, Tokyo, Japan) at an acceleration voltage of 100 kV. 
The loading amount of 5-FU into LDH was determined by 
ultraviolet-visible absorbance (UV-Vis) at 265 nm.
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cell lines and cell viability test: MTT assay
The colon cancer HCT-116 cell line was purchased from 
American Type Culture Collection (ATCC®) (Manassas, VA, 
USA) and the cells were maintained in complete DMEM, 
supplemented with 10% fetal calf serum, 1% penicillin, 
and 1% streptomycin, in 75 mL flasks at 37°C and 5% 
CO
2
. For the cytotoxicity assay, cells were trypsinized for 
5 minutes and resuspended in a medium to dilute the con-
centration to 1×105/mL. Then 100 µL of cells was added to 
each well in a 96-well plate for the cytotoxicity assay, under 
treatments of various concentrations of BEZ-235 and LDH-
5-FU. An MTT assay was used to measure cell viability, 
according to the manufacturer’s (Sigma-Aldrich, St Louis; 
MO) instructions.
cell cycle analysis
Propidium iodide (PI) was used to stain the DNA content. 
HCT-116 cells were harvested by trypinization and were 
washed with phosphate buffered saline (PBS). The cells 
were resuspended in PBS at 2×106/mL. With 1 mL of the 
resuspended cells, 1 mL of 100% cold ethanol was added 
dropwise and vortexed gently. The mixture was stored over-
night at -20°C. After washing the cells with cold PBS, they 
were resuspended in a 300 µL PI/Triton buffer containing 
0.01% Triton 100 (by volume) and 6 µg PI. After incubation 
at room temperature for 40 minutes, the stained cells were 
analyzed with flow cyto metry (Accuri™, BD Biosciences, 
Franklin Lakes, NJ, USA) and (FlowJo software, Tree Star 
Inc, Ashland, OR, USA).
cell apoptosis analysis
Cell apoptosis and cell death were detected using the Annexin 
V apoptosis kit, following the procedure recommended by 
the manufacturer (BD; Bioscienes, Franklin Lakes, NJ, 
USA). HCT-116 cells were cultured in a 6-well plate with 
2×105 cells in each well. Cells were treated for 24 hours with 
various concentrations of BEZ-235 ranging from 25–400 nm, 
and LDH-5-FU from 3–12 µg/mL. As well, a combinational 
treatment of BEZ-235 and LDH-5-FU was used. Treated cells 
were collected by centrifugation and suspended in 100 µL 
of the provided buffer and stained with Annexin V-FITC 
conjugates and PI for 15 minutes. Cell death and apoptosis 
were then detected by flow cytometry.
Data analysis
Data collected from each group (experimental and control) 
were expressed as mean ± standard deviation. The one-way 
ANOVA and unpaired Student’s t-test (Prism version 6, 
GraphPad Software Inc, La Jolla, CA, USA) were used to 
analyze the differences between groups and discriminate the 
significant differences between experimental and control 
groups (one-way ANOVA: P0.05).
Results
characterization of lDh and lDh-5-FU
As shown in Figure 1A, the synthesized LDH suspension 
had platelike particles with a hexagonal shape. The DLS 
data in Figures 1C and 1D indicated that the average size 
of LDH nanoparticles was ~109 nm with a zeta potential of 
+42.9 mV, consistent with our previous reports.15 After load-
ing 5-FU into LDH nanoparticles, LDH-5-FU nanohybrids 
presented a narrow particle size distribution in the range of 
50–150 nm and a zeta potential of +40.6 mV (Figures 1C and 
1D). Compared with LDH, the average size of LDH-5-FU 
decreased from 109 nm to 85 nm, as reported previously,15 
due to inhibition of the hydroxide layer growth by the anionic 
5-FU. The TEM image in Figure 1B shows that the LDH-
5-FU nanohybrid had a similar platelike morphology to the 
LDH nanoparticle. The amount of 5-FU loaded in LDH 
nanoparticles was 9.6% by weight, determined by UV-Vis.
cytotoxicity induced by 5-FU,  
lDh-5-FU, and BeZ-235
We compared the cytotoxicity of  LDH-5-FU with free 
5-FU on the colon cancer cell line HCT-116. In Figure 2A, 
it can be seen that both 5-FU and LDH-5-FU produced a 
dose-dependent cytotoxic effect on HCT-116 cells after 
24 hour treatment. LDH-5-FU has much higher cytotoxic-
ity than free 5-FU. It started to show the effect at 3 µg/mL, 
with an increased effect at 6 µg/mL, and the number of 
surviving cells decreased to about 20% at 12 µg/mL. The 
half maximal inhibitory concentration (IC
50
) for the inhibi-
tory effect of LDH-5-FU on HCT-116 is 5.585 µg/mL. 
The free 5-FU had much lower cytotoxicity and it only 
reduced cell viability to 56%, even at 48 µg/mL. We chose 
6 µg/mL for the study because of its combinatorial effect 
with BEZ-235.
In order to select a dose of BEZ-235 to test the effect 
of combination treatment of LDH-5-FU and BEZ-235, the 
effect of BEZ-235 on HCT-116 cells was tested at differ-
ent doses. After 24 hour incubation, BEZ-235 produced 
dose-dependent cytotoxicity on HCT-116 cells in the dose 
range from 50–400 nm (Figure 2B). IC
50
 for the inhibi-
tory effect of BEZ-235 on HCT-116 cells is 78.2 nm. We 
chose the concentration of 100 nm for the combination 
treatment.
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Figure 1 Featured structure of lDh and lDh-5-FU nanohybrids.
Notes: (A–B) Tranmission electron microscopy images of lDh and lDh-5-FU. The scale bar represents 200 nm. (C) Particle size distribution of lDh and lDh-5-FU from 
dynamic light scattering. (D) Zeta potential of lDh and lDh-5-FU.
Abbreviations: LDH, layered double hydroxide; 5-FU, fluorouracil.
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More effective inhibition by the 
combination of lDh-5-FU and BeZ-235
Figure 3 showed that LDH-5-FU and BEZ-235 together 
produced a higher cytotoxic effect. It is shown that both LDH-
5-FU and BEZ-235 alone produced a middle range of cyto-
toxicity to HCT-116 cells. Treatment with BEZ-235 alone 
at 100 nm decreased cell survival to 46% of the control. 
Treatment with LDH-5-FU at 6 µg/mL alone decreased the 
survival rate to 56%. However, the combination use of the 
two drugs resulted in massive cell death, reducing survival 
rate to 8% of the control. The cell survival rate was signifi-
cantly lower than both LDH-5-FU and BEZ-235 treatments 
alone. Therefore, BEZ-235 increases the sensitivity of 
HCT-116 to LDH-5-FU treatment. These data clearly show 
that a combination treatment with BEZ-235 and LDH-5-FU 
remarkably suppresses HCT-116 cell growth.
combination treatment of lDh-5-FU  
and BeZ-235 caused more g1 arrest
It was reported that BEZ-235 could induce cell cycle G1 
arrest in the prostate cancer cell line PC3M.32 To examine 
whether combination treatment with LDH-5-FU and BEZ-
235 has the same effect, we carried out a cell cycle analysis. 
The result showed that the combination treatment remark-
ably increased the Sub-G1 (apoptotic) population (51.85%) 
(Figure 4), compared with single drug treatments (16.75% 
and 23.05%, for LDH-5-FU and BEZ-235, respectively) 
and the untreated control (Figure 4). Instead of G1 arrest, 
we observed a remarkable decrease in the G1 phase and an 
increase of population at the G2/Mitotic (G2/M) phase after 
the combination treatment (Figure 4).
lDh-5-FU and BeZ-235 caused cell 
death and apoptosis
We further assayed the combination treatment effect of 
LDH-5-FU and BEZ-235 on cell death using the Annexin 
V apoptosis kit. As shown in Figure 5, both LDH-5-FU and 
BEZ-235 produced cell death and apoptosis after 24 hour 
treatment. LDH-5-FU alone, at 6 µg/mL, resulted in 28% 
cell apoptosis and death. Treatment with BEZ-235 alone, at 
100 nm, led to 9% cell apoptosis and cell death. However, the 
combinatorial application of both agents produced a greater 
effect, resulting in 46% cell apoptosis and death. Compared 
with the control, the LDH-5-FU treatment caused some early 
apoptosis (10.76% versus 1.09%) (Figures 5A and 5B) and 
this effect was carried on into the combination treatment 
(10.68%) (Figure 5C). BEZ-235 treatment alone did not 
induce much early apoptosis (Figure 5D). In addition, LDH-
5-FU (Figure 5B) and combination treatments (Figure 5C) 
caused much more necrotic cell death (right upper quar-
ters) than either BEZ-235 alone (Figure 5D) or the control 
(Figure 5A). We further analyzed Bcl-2 protein levels (an 
antiapoptotic protein associated with mitochondria apoptosis 
pathways) and found that treatment with a single drug led to 
the reduction of this protein. The most significant reduction 
was seen in the combination treatment (Figure 5E), which 
is consistent with the above results.
Discussion
Fluorouracil is a common chemotherapeutic agent used 
in the treatment of colon cancer. It is a suicide inhibitor 
of thymidylate synthase, an enzyme necessary for DNA 
replication.33,34 Fluorouracil is very toxic to normal cells and 
causes severe side effects at the therapeutic dosage, includ-
ing damage to bone marrow, the gastrointestinal tract, and 
skin.35,36 To reduce side effects, its dose must be decreased 
through combinational application with other drugs or drug 
delivery systems. In this study, we used LDH to lower the 
dose of 5-FU, at which higher cytotoxicity to cancer cells 
still remained. We also tested the combination treatment of 
LDH-loaded 5-FU with BEZ-235.
Nanoparticles have been extensively used for drug delivery, 
to increase drug efficacy and reduce side effects. In our study, 
we showed that nanodelivered 5-FU increased cytotoxicity to 
HCT-116 markedly. This may be due to the endocytosis effect. 
In this process, LDH-5-FU is engulfed by HCT-116 cells as 
Figure 3 combination treatment of BeZ-235 and lDh-5-FU to hcT-116 cells.
Notes: The MTT assay result shows that the combinational treatment with BeZ-
235 at 100 nm and lDh-5-FU at 6 µg/ml is much more effective at reducing cancer 
cell viability than any treatments with a single drug.
Abbreviations: LDH, layered double hydroxide; 5-FU, fluorouracil.
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Figure 4 cell cycle analysis of hcT-116 cells treated with BeZ-235 and lDh-5-FU.
Notes: The flow cytometry result shows the cell cycle analysis of DNA contents labeled by PI which is shown by the FL2 channel.
Abbreviations: LDH, layered double hydroxide; 5-FU, fluorouracil; PI, propidium iodide.
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a particle, which contains more 5-FU molecules than free 
5-FU.37 This process facilitates entry of 5-FU into cells and 
therefore results in higher cytotoxicity. So far, LDH-5-FU has 
only been tested with curcumin as a  combinational treatment 
on cancer cells, where LDH-5-FU has been shown to have a 
synergistic effect with solid lipid nanoparticle-curcumin.5 In 
our study, we tested the effect of LDH-5-FU on HCT-116 cells 
in combination with BEZ-235, a newly-invented PI3K/Akt 
inhibitor for colon cancer treatment.
The rationale behind applying 5-FU and a PI3K/Akt 
inhibitor is based on the effectiveness of inhibition of the 
pathway in colon cancer treatment.38–40 We have shown that 
activation of the PI3K/Akt pathway can reduce the effect of 
chemotherapeutic agents, including 5-FU, on colon cancer 
cell lines.41,42 Inhibition of the pathway increased the sensi-
tivity of HT-29 cells to 5-FU. Leptin has also been shown 
to increase colon cancer resistance to 5-FU treatment, via 
activation of the PI3K/Akt pathway.43 Chen et al showed 
that siRNA knockdown of focal adhesion kinase (FAK) 
reduced Akt activity and increased colon cancer sensitivity to 
5-FU.44 Recently, Liao et al showed that regular use of aspirin 
increased the survival time of colorectal cancer patients with 
the mutated PIK3CA gene but not of those with the wild-type 
PIK3CA.45 The effectiveness of BEZ-235 has been extensively 
tested in PIK3CA-mutated colon cancer cell lines.31 Therefore, 
it is useful for the combination study with LDH-5-FU.
Our study shows for the first time that the dual inhibitor 
of the PI3K/Akt/mTOR pathway, BEZ-235, can sensitize 
HCT-116 cells to LDH loaded with 5-FU. This is a novel 
approach for the treatment of colon cancer. HCT-116 cells 
have a mutation in PIK3CA. Therefore, their PI3K pathway 
is highly-activated and thus is sensitive to inhibition of the 
pathway. BEZ-235 has been used for several clinical trials 
in colon cancer treatment. The approach we tested could be 
applicable for clinical trials, as both BEZ-235 and 5-FU are 
approved for clinical use as anticancer agents. BEZ-235 is 
known to have minor side effects. Several studies showed 
that it is well-tolerated in clinical trials. 5-FU is a traditional 
therapy drug for colon cancer. LDH is also a low toxicity 
nanoparticle. In our study, the concentration of 5-FU is 
300 µg/mL and the concentration of LDH is 4 mg/mL. At 
the concentration of 6 µg/mL of 5-FU, the concentration of 
LDH is 80 µg/mL. At this concentration of LDH, it has no 
toxicity to normal cells.
Muller et al studied the effect of BEZ-235 and irinotecan 
on HT-29 cells and showed that BEZ-235 increased the 
effect of irinotecan.46 This study indicated that inhibition 
of the PI3K/Akt/mTOR pathway can be combined with a 
 chemotherapeutic agent to increase treatment efficacy in 
colon cancer. However, only irinotecan was tested. 5-FU 
and other chemotherapeutic agents commonly used in colon 
cancer treatment were not tested.
A dual inhibitor of the PI3K/Akt/mTOR pathway, PI-103, 
has been shown to increase the efficacy of 5-FU in both in 
vitro and in vivo studies in gastric cancer.24 In comparison 
with single inhibitors of PI3K and mTOR, PI-103 produced 
an enhanced effect. PI-103 is the first-identified dual inhibitor 
of the PI3K and mTOR pathways. Although it has a strong 
antitumor effect, it is not suitable for clinical applica-
tion, due to its high toxicity.47,48 In contrast, BEZ-235 has 
been extensively tested in clinical trials for many types of 
cancers, and has demonstrated high effectiveness and low 
toxicity.39,40,49–52 In the present study, we applied BEZ-235 in 
colon cancer HCT-116 in combination with LDH-5-FU to 
demonstrate their combination effect.
Our study has partially elucidated the mechanisms for 
the combination effect of BEZ-235 and LDH-5-FU. In cell 
cycle analysis, the combination treatment produced many 
more sub-G1 apoptotic cells than BEZ-235 or LDH-5-FU 
alone, indicating the additive effect on cell death of the two 
drugs. Cell cycle arrest was observed in the G2/M phase, 
with a remarkable decrease of the G1 phase. This differs from 
another study, which showed that BEZ-235 caused G1 arrest 
in PC3M cells.32 The difference could be caused by the differ-
ent cell types and drug doses used. In that study, 10 nm and 
50 nm of BEZ-235 were used. The combination treatment 
produced more reduction in Bcl-2. Bcl-2 is an antiapoptotic 
protein and its reduction could lead to increased apoptosis. 
Therefore, both cell proliferation and cell apoptosis are 
affected by the combination treatment. Further studies are 
warranted, so that the combination application can be used 
for clinical trials.
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